Stock Financial Ratios, Dividends, Split History

MRTX / Mirati Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)888.46
Enterprise Value ($M)780.76
Book Value ($M)137.84
Book Value / Share4.74
Price / Book6.20
NCAV ($M)136.37
NCAV / Share4.69
Price / NCAV10.43
Share Statistics
Common Stock Shares Outstanding 28,622,886
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 28,940,161
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.49
Return on Assets (ROA)-1.11
Return on Equity (ROE)-1.46
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio9.56
Income Statement (mra) ($M)
License And Services Revenue0.00
Operating Income-71.53
Net Income-70.43
Earnings Per Share Diluted-70,430,000.00
Earnings Per Share Basic-2.78
Cash Flow Statement (mra) ($M)
Cash From Operations-64.71
Cash from Investing-8.65
Cash from Financing-8.65
Identifiers and Descriptors
Central Index Key (CIK)1576263
Related CUSIPS
60468T905 60468T955

Split History

Stock splits are used by Mirati Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

2018-06-15 zacks
Looking for broad exposure to the Small Cap Blend segment of the US equity market? You should consider the PowerShares DWA SmallCap Momentum Portfolio (DWAS - Free Report) , a passively managed exchange traded fund launched on 07/19/2012. (74-0)

ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed

2018-06-13 seekingalpha
Trump-Kim summit has the potential to be market-moving, if adverse, but most likely it will be a non-event. (302-0)

Your Daily Pharma Scoop: Secondaries Review June 4-11

2018-06-12 seekingalpha
Using a set of 3 criterion, we have singled out MEI Pharma's offering for an analysis. (169-5)

Institutional Top Ideas: EcoR1 Capital

2018-06-12 seekingalpha
Returns for EcoR1 Capital are quite impressive. It is significantly differentiated from peers with a higher percent of the portfolio in its top 10 positions and a higher turnover rate. (204-1)

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high. (474-6)

CUSIP: 60468T105